Display options
Cite
Mitchell JL, Pollara J, Dietze K, et al. Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. J Clin Invest. 2022;132(1)doi: 10.1172/JCI150937.
Mitchell, J. L., Pollara, J., Dietze, K., Edwards, R. W., Nohara, J., N'guessan, K. F., Zemil, M., Buranapraditkun, S., Takata, H., Li, Y., Muir, R., Kroon, E., Pinyakorn, S., Jha, S., Manasnayakorn, S., Chottanapund, S., Thantiworasit, P., Prueksakaew, P., Ratnaratorn, N., Nuntapinit, B., Fox, L., Tovanabutra, S., Paquin-Proulx, D., Wieczorek, L., Polonis, V. R., Maldarelli, F., Haddad, E. K., Phanuphak, P., Sacdalan, C. P., Rolland, M., Phanuphak, N., Ananworanich, J., Vasan, S., Ferrari, G., Trautmann, L. (2022). Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. The Journal of clinical investigation, 132(1), . https://doi.org/10.1172/JCI150937
Mitchell, Julie L, et al. "Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection." The Journal of clinical investigation vol. 132,1 (2022). doi: https://doi.org/10.1172/JCI150937
Mitchell JL, Pollara J, Dietze K, Edwards RW, Nohara J, N'guessan KF, Zemil M, Buranapraditkun S, Takata H, Li Y, Muir R, Kroon E, Pinyakorn S, Jha S, Manasnayakorn S, Chottanapund S, Thantiworasit P, Prueksakaew P, Ratnaratorn N, Nuntapinit B, Fox L, Tovanabutra S, Paquin-Proulx D, Wieczorek L, Polonis VR, Maldarelli F, Haddad EK, Phanuphak P, Sacdalan CP, Rolland M, Phanuphak N, Ananworanich J, Vasan S, Ferrari G, Trautmann L. Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. J Clin Invest. 2022 Jan 04;132(1). doi: 10.1172/JCI150937. PMID: 34762600.
Copy Download .nbib Format: NLM
Share it on

J Clin Invest. 2022 Jan 04;132(1). doi: 10.1172/JCI150937.

Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.

The Journal of clinical investigation

Julie L Mitchell, Justin Pollara, Kenneth Dietze, R Whitney Edwards, Junsuke Nohara, Kombo F N'guessan, Michelle Zemil, Supranee Buranapraditkun, Hiroshi Takata, Yifan Li, Roshell Muir, Eugene Kroon, Suteeraporn Pinyakorn, Shalini Jha, Sopark Manasnayakorn, Suthat Chottanapund, Pattarawat Thantiworasit, Peeriya Prueksakaew, Nisakorn Ratnaratorn, Bessara Nuntapinit, Lawrence Fox, Sodsai Tovanabutra, Dominic Paquin-Proulx, Lindsay Wieczorek, Victoria R Polonis, Frank Maldarelli, Elias K Haddad, Praphan Phanuphak, Carlo P Sacdalan, Morgane Rolland, Nittaya Phanuphak, Jintanat Ananworanich, Sandhya Vasan, Guido Ferrari, Lydie Trautmann,

Affiliations

  1. Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.
  2. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  3. Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, Maryland, USA.
  4. Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  5. Department of Medicine and.
  6. Center of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  7. Department of Medicine, Division of Infectious Diseases and HIV Medicine, Drexel University, Philadelphia, Pennsylvania, USA.
  8. Institute of HIV Research and Innovation (IHRI), Bangkok, Thailand.
  9. Bamrasnaradura Infectious Disease Institute, Nonthaburi, Thailand.
  10. Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand.
  11. Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  12. HIV Dynamics and Replication Program, National Cancer Institute (NCI), NIH, Frederick, Maryland, USA.
  13. Department of Global Health, University of Amsterdam, Amsterdam, Netherlands.

PMID: 34762600 DOI: 10.1172/JCI150937

Abstract

Early initiation of antiretroviral therapy (ART) in acute HIV infection (AHI) is effective at limiting seeding of the HIV viral reservoir, but little is known about how the resultant decreased antigen load affects long-term Ab development after ART. We report here that Env-specific plasma antibody (Ab) levels and Ab-dependent cellular cytotoxicity (ADCC) increased during the first 24 weeks of ART and correlated with Ab levels persisting after 48 weeks of ART. Participants treated in AHI stage 1 had lower Env-specific Ab levels and ADCC activity on ART than did those treated later. Importantly, participants who initiated ART after peak viremia in AHI developed elevated cross-clade ADCC responses that were detectable 1 year after ART initiation, even though clinically undetectable viremia was reached by 24 weeks. These data suggest that there is more germinal center (GC) activity in the later stages of AHI and that Ab development continues in the absence of detectable viremia during the first year of suppressive ART. The development of therapeutic interventions that can enhance earlier development of GCs in AHI and Abs after ART initiation could provide important protection against the viral reservoir that is seeded in individuals treated early in the disease.

Keywords: AIDS/HIV; Immunoglobulins; Immunology

Publication Types